Effects of pioglitazone and metformin on β-cell function in nondiabetic subjects at high risk for type 2 diabetes

被引:20
|
作者
Rasouli, Neda
Kern, Philip A.
Reece, E. Albert
Elbein, Steven C.
机构
[1] Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA
[2] Univ Arkansas Med Sci, Coll Med, Dept Med, Div Endocrinol, Little Rock, AR USA
[3] Univ Arkansas Med Sci, Coll Med, Dept Obstet & Gynecol, Little Rock, AR USA
关键词
insulin sensitizer; prediabetes;
D O I
10.1152/ajpendo.00221.2006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Effects of pioglitazone and metformin on beta-cell function in nondiabetic subjects at high risk for type 2 diabetes. Am J Physiol Endocrinol Metab 292:E359-E365, 2007. First published September 12, 2006;doi:10.1152/ajpendo.00221.2006. Thiazolidinediones (TZDs) and metformin decreased the incidence of diabetes in subjects at risk for developing diabetes and improved peripheral or hepatic insulin sensitivity, respectively. Whether they also directly improved beta-cell function is not clear. In vitro studies showed improved beta-cell function in response to TZDs and metformin; however, the effects of TZDs or metformin on beta-cell function in humans are still uncertain. We hypothesized that both TZDs and metformin directly affect beta-cell function. We evaluated beta-cell function and insulin sensitivity (SI) in subjects with impaired glucose tolerance or a history of gestational diabetes using oral and intravenous glucose tolerance tests in addition to the glucose-potentiated arginine stimulation test. In contrast to metformin, pioglitazone improved S-I, glucose tolerance, and insulin-independent glucose disposal [glucose effectiveness (SG)]. Neither pioglitazone nor metformin significantly improved beta-cell compensation for insulin resistance [disposition index (DI)], but the change in DI significantly correlated with baseline SI. Insulin secretion in response to arginine at maximally potentiating glucose levels (AIR(max)) tended to increase after metformin and to decrease after pioglitazone; however, when adjusted for SI, the changes were not significant. Our results demonstrate that, in nondiabetic subjects at risk for diabetes, pioglitazone, but not metformin, significantly improved glucose tolerance by improving SI and SG. We did not find any evidence that either pioglitazone or metformin improved beta-cell function. Improved beta-cell compensation was observed primarily in the subgroup of subjects that had the lowest SI at baseline.
引用
收藏
页码:E359 / E365
页数:7
相关论文
共 50 条
  • [1] Effects of pioglitazone and metformin on blood pressure in type 2 diabetes
    Lawrence, JM
    Reid, J
    Taylor, GJ
    Stirling, C
    Reckless, JPD
    ATHEROSCLEROSIS, 2003, 169 (02) : 357 - 357
  • [2] Effects of pioglitazone versus metformin on endothelial function in patients with type 2 diabetes treated with sulfonylureas
    Naka, K. K.
    Papathanassiou, K.
    Bechlioulis, A.
    Pappas, K.
    Kazakos, N.
    Kanioglou, C.
    Vezyraki, P.
    Makriyiannis, D.
    Tsatsoulis, A.
    Michalis, L. K.
    EUROPEAN HEART JOURNAL, 2011, 32 : 65 - 66
  • [3] Effects of pioglitazone and metformin on vascular endothelial function in patients with type 2 diabetes treated with sulfonylureas
    Naka, Katerina K.
    Papathanassiou, Katerina
    Bechlioulis, Aris
    Pappas, Konstantinos
    Kazakos, Nikolaos
    Kanioglou, Chryssanthi
    Kostoula, Aggeliki
    Vezyraki, Patra
    Makriyiannis, Demetrios
    Tsatsoulis, Agathocles
    Michalis, Lampros K.
    DIABETES & VASCULAR DISEASE RESEARCH, 2012, 9 (01): : 52 - 58
  • [4] Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin
    DeFronzo, Ralph A.
    Triplitt, Curtis
    Qu, Yongming
    Lewis, Michelle S.
    Maggs, David
    Glass, Leonard C.
    DIABETES CARE, 2010, 33 (05) : 951 - 957
  • [5] Effects of metformin on the body composition in subjects with risk factors for type 2 diabetes
    Rodríguez-Moctezuma, JR
    Robles-López, G
    López-Carmona, JM
    Gutiérrez-Rosas, MJ
    DIABETES OBESITY & METABOLISM, 2005, 7 (02): : 189 - 192
  • [6] Favourable effects of pioglitazone and metformin on LDL subfractions in type 2 diabetes
    Lawrence, JM
    Reid, J
    Taylor, GJ
    Stirling, C
    Reckless, JPD
    ATHEROSCLEROSIS, 2003, 169 (02) : 358 - 358
  • [7] Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide
    Belcher, G
    Lambert, C
    Goh, KL
    Edwards, G
    Valbuena, M
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (09) : 833 - 837
  • [8] The Effects of Semaglutide on β-cell Function in Subjects with Type 2 Diabetes
    Kapitza, Christoph
    Dahl, Kirsten
    Jacobsen, Jacob Bonde
    Axelsen, Mads Buhl
    Flint, Anne
    DIABETES, 2016, 65 : A262 - A263
  • [9] Effect of Pioglitazone Versus Metformin on Cardiovascular Risk Markers in Type 2 Diabetes
    Genovese, Stefano
    De Berardis, Giorgia
    Nicolucci, Antonio
    Mannucci, Edoardo
    Evangelista, Virgilio
    Totani, Licia
    Pellegrini, Fabio
    Ceriello, Antonio
    ADVANCES IN THERAPY, 2013, 30 (02) : 190 - 202
  • [10] Effect of Pioglitazone Versus Metformin on Cardiovascular Risk Markers in Type 2 Diabetes
    Stefano Genovese
    Giorgia De Berardis
    Antonio Nicolucci
    Edoardo Mannucci
    Virgilio Evangelista
    Licia Totani
    Fabio Pellegrini
    Antonio Ceriello
    Advances in Therapy, 2013, 30 : 190 - 202